Abstract Details
|
Tali R. Sorets
PRESENTER |
Tali R. Sorets has nothing to disclose. |
| Erica McKenzie, MD (University of Calgary, Department of Clinical Neurosciences) | Dr. McKenzie has nothing to disclose. |
| Amanda P. Jones | No disclosure on file |
| No disclosure on file | |
| Sydney Cash, MD (Massachusetts General Hospital) | Dr. Cash has received stock or an ownership interest from Beacon Biosignals. |
| Edward C. Leung, MD (Health Sciences Centre) | No disclosure on file |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| Farrah J. Mateen, MD, PhD, FAAN (Northwestern University Department of Neurology) | Dr. Mateen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Mateen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Mateen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Mateen has received research support from Genentech. The institution of Dr. Mateen has received research support from Amgen. The institution of Dr. Mateen has received research support from TG Therapeutics. Dr. Mateen has received intellectual property interests from a discovery or technology relating to health care. |